International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

Mental Health Assessment in Patients Admitted to Iran Psychiatric Hospital with a Diagnosis of Psychosis Due to 2 - 5 Years of Methamphetamine Use

Hamid Reza Ahmadkhaniha 1 , Kaveh Alavi 2 , Elham Rouhi 1 , * and Mohammad Reza Najarzadegan 1
Authors Information
1 Research Centre for Addiction and Risky Behaviors (ReCARB), Department of Psychiatry, Iran University of Medical Sciences, Tehran, IR Iran
2 Mental Health Research Center, Department of Psychiatry, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • International Journal of High Risk Behaviors and Addiction: June 2018, 7 (2); e64561
  • Published Online: May 21, 2018
  • Article Type: Research Article
  • Received: November 28, 2017
  • Accepted: January 10, 2018
  • DOI: 10.5812/ijhrba.64561

To Cite: Ahmadkhaniha H R, Alavi K, Rouhi E, Najarzadegan M R. Mental Health Assessment in Patients Admitted to Iran Psychiatric Hospital with a Diagnosis of Psychosis Due to 2 - 5 Years of Methamphetamine Use, Int J High Risk Behav Addict. 2018 ; 7(2):e64561. doi: 10.5812/ijhrba.64561.

Abstract
Copyright © 2018, International Journal of High Risk Behaviors and Addiction. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Loberg EM, et al. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12:221. doi: 10.1186/1471-244X-12-221. [PubMed: 23216941]. [PubMed Central: PMC3554477].
  • 2. United nations secretariat secretary. General's bulletin organization of the united nations office on drugs and crime. 2004.
  • 3. Jaffe JH, Ling W, Rawson RA. Amphetamine (or amphetamine like)-related disorders. In: Sadock B, Sadock V, Pedro R, editors. Kaplan and sadock's comprehensive textbook of psychiatry. New York: Lippincott Williams and Wilkins; 2009.
  • 4. Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine-induced psychosis. J Ment Health. 2013;22(4):341-9. doi: 10.3109/09638237.2012.745184. [PubMed: 23323572].
  • 5. Akiyama K, Saito A, Shimoda K. Chronic methamphetamine psychosis after long-term abstinence in Japanese incarcerated patients. Am J Addict. 2011;20(3):240-9. doi: 10.1111/j.1521-0391.2011.00124.x. [PubMed: 21477052].
  • 6. Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, Thummawomg P, Dumrongchai U, Chutha W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev. 2010;29(4):456-61. doi: 10.1111/j.1465-3362.2010.00196.x. [PubMed: 20636664].
  • 7. Ikeda M, Okahisa Y, Aleksic B, Won M, Kondo N, Naruse N, et al. Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia. Neuropsychopharmacology. 2013;38(10):1864-70. doi: 10.1038/npp.2013.94. [PubMed: 23594818]. [PubMed Central: PMC3746703].
  • 8. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry. 2012;169(4):389-96. doi: 10.1176/appi.ajp.2011.10070937. [PubMed: 22193527].
  • 9. Sulaiman AH, Said MA, Habil MH, Rashid R, Siddiq A, Guan NC, et al. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia. Compr Psychiatry. 2014;55 Suppl 1:S89-94. doi: 10.1016/j.comppsych.2013.01.003. [PubMed: 23433219].
  • 10. Lecomte T, Mueser KT, MacEwan W, Thornton AE, Buchanan T, Bouchard V, et al. Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment. J Nerv Ment Dis. 2013;201(12):1085-9. doi: 10.1097/NMD.0000000000000059. [PubMed: 24284645].
  • 11. Mehrjerdi ZA, Abarashi Z, Noroozi A, Arshad L, Zarghami M. Correlates of shared methamphetamine injection among methamphetamine-injecting treatment seekers: the first report from Iran. Int J STD AIDS. 2014;25(6):420-7. doi: 10.1177/0956462413512806. [PubMed: 24287028].
  • 12. Asnafi S, Sharifi V, Tehranidoost M. Negative priming in amphetamine psychosis. Psychiatry Res. 2013;210(1):263-7. doi: 10.1016/j.psychres.2013.05.027. [PubMed: 23773294].
  • 13. Eghtedari A, Shariat V, Farahani H. [Cognitive functions in patients with methamphetamine-induced psychosis in comparison with a healthy control group]. Adv Cogn Sci. 2012;13(4):19-26. Persian.
  • 14. Barati M, Ahmadpanah M, Soltanian AR. Prevalence and factors associated with methamphetamine use among adult substance abusers. J Res Health Sci. 2014;14(3):221-6. [PubMed: 25209911].
  • 15. Morasco BJ, O'Neil ME, Duckart JP, Ganzini L. Comparison of health service use among veterans with methamphetamine versus alcohol use disorders. J Addict Med. 2014;8(1):47-52. doi: 10.1097/ADM.0000000000000005. [PubMed: 24365802].
  • 16. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci. 2004;1025:279-87. doi: 10.1196/annals.1316.035. [PubMed: 15542728].
  • 17. Hellem TL, Lundberg KJ, Renshaw PF. A review of treatment options for co-occurring methamphetamine use disorders and depression. J Addict Nurs. 2015;26(1):14-23. quiz E1. doi: 10.1097/JAN.0000000000000058. [PubMed: 25761159]. [PubMed Central: PMC5510330].
  • 18. Moon K, Albuquerque FC, Mitkov M, Ducruet AF, Wilson DA, Crowley RW, et al. Methamphetamine use is an independent predictor of poor outcome after aneurysmal subarachnoid hemorrhage. J Neurointerv Surg. 2015;7(5):346-50. doi: 10.1136/neurintsurg-2014-011161. [PubMed: 24780822].
  • 19. Yew KL, Go CS, Razali F, Rajendran P, Ooi PS, Anum A. Methamphetamine-associated reversible cardiomyopathy and stroke risk. Eur Rev Med Pharmacol Sci. 2014;18(17):2403-4. [PubMed: 25268081].
  • 20. Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(1):e94-9. doi: 10.4088/JCP.12m07822. [PubMed: 23419236].
  • 21. Li H, Lu Q, Xiao E, Li Q, He Z, Mei X. Methamphetamine enhances the development of schizophrenia in first-degree relatives of patients with schizophrenia. Can J Psychiatry. 2014;59(2):107-13. doi: 10.1177/070674371405900206. [PubMed: 24881129]. [PubMed Central: PMC4079234].
  • 22. Pluddemann A, Dada S, Parry CD, Kader R, Parker JS, Temmingh H, et al. Monitoring the prevalence of methamphetamine-related presentations at psychiatric hospitals in Cape Town, South Africa. Afr J Psychiatry (Johannesbg). 2013;16(1):45-9. [PubMed: 23417636].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments